GlobalData on MSN

Sound Pharmaceuticals concludes subject enrolment for SPI-1005 trial

The purpose of the trial is to collect additional safety data supporting chronic daily dosing of SPI-1005.

Sound Pharma completes enrollment of Open Label Phase 3 study of SPI-1005 in Meniere’s Disease

Sound Pharmaceuticals is pleased to announce that it completed enrollment of its second Phase 3 open label study of SPI-1005 ...
Nasdaq

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

PONTE VEDRA, Fla., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (Nasdaq: CVKD), a biopharmaceutical company developing transformative therapeutics to overcome the limitations of ...